Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Spark Therap (NQ: ONCE )

N/A USD UNCHANGED
Last Price Updated: 12:31 PM EST, Dec 17, 2019 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Spark Therap

< Previous 1 2 3 4 5 6 Next >
Spark Therapeutics Announces First-of-their-kind Programs to Improve Patient Access to LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy Treatment
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced three new payer programs: an outcomes-based... 
From GlobeNewswire News Releases
Pre-Market Technical Scan on Biotech Equities -- Grifols, Advaxis, Nektar Therapeutics, and Spark Therapeutics
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on GRFS, ADXS, NKTR, and ONCE which can be accessed for free by signing up to... 
From PR Newswire
Spark Therapeutics to Participate in Multiple Conferences in January
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that Jeffrey D. Marrazzo, chief executive... 
From GlobeNewswire News Releases
FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that the U.S. Food and Drug Administration (FDA)... 
From GlobeNewswire News Releases
Spark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting and Expo
Preliminary data as of Dec. 6, 2017, show a 100-percent reduction in annualized bleeding rate (ABR) and 98-percent reduction in annualized infusion rate (AIR) in first four participants 
From GlobeNewswire News Releases
Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Ex
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. (NYSE:PFE), today announced that, with a... 
From GlobeNewswire News Releases
Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
Annualized bleeding rate (ABR) among 10 participants was reduced 97 percent following SPK-9001 administration, while factor IX concentrate use collectively was reduced 99 percent by 1.95 million... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical Trials at 59th American Society of Hematology Annual Meeting and Exposition
Investor teleconference to be held Monday, Dec. 11, at 12:30 p.m.ET 
From GlobeNewswire News Releases
Stock Review for Biotech's Investors -- Spark Therapeutics, Agenus, Coherus Biosciences, and Acorda Therapeutics
From PR Newswire
Three-year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational LUXTURNA™ (voretigene neparvovec) in Patients with Biallelic RPE65-mediated Inher
Data show mean improvement demonstrated at one year post one-time administration maintained through at least three years for original intervention cohort, and two years for crossover cohort, with... 
From GlobeNewswire News Releases
Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today financial results for the third quarter of 2017... 
From GlobeNewswire News Releases
Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B
Spark Therapeutics to receive up to an additional $25 million per terms of amendment 
From GlobeNewswire News Releases
Spark Therapeutics to Participate in Multiple Upcoming Conferences
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that members of company management or principal... 
From GlobeNewswire News Releases
Spark Therapeutics to Host Conference Call on Tuesday, Nov. 7 at 8:30 a.m. ET to Discuss Third Quarter 2017 Results
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Nov. 7, 2017, at 8:30... 
From GlobeNewswire News Releases
Biotech Stocks on Investors' Radar -- Nektar Therapeutics, Ophthotech, PTC Therapeutics, and Spark Therapeutics
From PR Newswire
FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA™ (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that the U.S. Food and Drug Administration’s... 
From GlobeNewswire News Releases
Spark Therapeutics (ONCE) Trading of Stock Halted as FDA Advisory Committee Reviews Investigational Gene Therapy
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that NASDAQ has halted trading of its common... 
From GlobeNewswire News Releases
Spark Therapeutics to Participate in Multiple Conferences in October
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that company management will present at the... 
From GlobeNewswire News Releases
Spark Therapeutics Further Expands Gene Therapy Expertise with Appointment of Federico Mingozzi, Ph.D., as Chief Scientific Officer
Katherine A. High, M.D., will continue to serve as president and head of R&D 
From GlobeNewswire News Releases
Spark Therapeutics Enters into Licensing Agreement with Genethon
Includes exclusive worldwide rights to adeno-associated viral (AAV) gene therapy targeting the liver 
From GlobeNewswire News Releases
Spark Therapeutics Announces Publication of Study Confirming Novel Test’s Validity, Reliability and Ability to Detect Change in Functional Vision
Multi-luminance mobility test (MLMT) was the primary endpoint in the Phase 3 trial for investigational LUXTURNA™ (voretigene neparvovec) 
From GlobeNewswire News Releases
Spark Therapeutics to Participate in Multiple Conferences in September
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that company management will present at or... 
From GlobeNewswire News Releases
Spark Therapeutics Recognized as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has been named one of the Philadelphia... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Closing of Public Offering
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today the closing of the previously announced underwritten public offering of its common stock pursuant to an automatically effective shelf... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Pricing of $350.0 Million Public Offering
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today the pricing of an underwritten public offering of 4,605,264 shares of its common stock pursuant to an automatically effective shelf... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Proposed Public Offering of Common Stock
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that it has commenced an underwritten public offering of $300,000,000 in shares of its common stock. Spark also intends to grant the... 
From GlobeNewswire News Releases
Spark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today financial results for the second quarter of 2017... 
From GlobeNewswire News Releases
Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA™ (voretigene neparvovec)
Potential for first gene therapy for a genetic disease to be approved in both the U.S. and EU 
From GlobeNewswire News Releases
Spark Therapeutics to Host Conference Call on Wednesday, Aug. 2 at 8:30 a.m. ET to Discuss Second Quarter 2017 Results
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Wednesday, Aug. 2, 2017 at 8:30... 
From GlobeNewswire News Releases
Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA™ (voretigene neparvovec) from FDA
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that the Offices of Orphan Products Development... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.